NEW YORK, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today the closing of its previously announced initial public offering of 3,815,291 shares of common stock, including the exercise in full of the over-allotment option covering 497,647 shares, at a public offering price of $10.00 per share. The gross proceeds to Stemline from the offering, including the exercise of the over-allotment option, were $38,152,910, before deducting underwriting discounts and commissions and other offering expenses payable by Stemline.
Aegis Capital Corp. acted as sole book-running manager for the offering.
Feltl and Company, Inc. and Sunrise Securities Corp. acted as co-managers for the offering.A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 28, 2013. This offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting the representative of the underwriters (as set forth below) or by accessing the SEC's website at www.sec.gov . Aegis Capital Corp. Prospectus Department 810 Seventh Avenue, 18th Floor New York, NY 10019 Telephone: 212-813-1010 E-mail: email@example.com About Stemline: Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that targets both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity, including durable complete responses (CRs), and an overall survival (OS) benefit versus historical controls in Phase 1/2 studies of advanced cancer patients. For more information about Stemline Therapeutics, visit www.stemline.com . Forward-Looking Statements This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Stemline: Mark Jacobson Director, Corporate Development Stemline Therapeutics, Inc. 750 Lexington Avenue Sixth Floor New York, NY 10022 Tel: 646-502-2307 Email: firstname.lastname@example.org